全文获取类型
收费全文 | 160453篇 |
免费 | 14268篇 |
国内免费 | 8638篇 |
专业分类
耳鼻咽喉 | 405篇 |
儿科学 | 4902篇 |
妇产科学 | 729篇 |
基础医学 | 10500篇 |
口腔科学 | 839篇 |
临床医学 | 21811篇 |
内科学 | 32169篇 |
皮肤病学 | 682篇 |
神经病学 | 8947篇 |
特种医学 | 7624篇 |
外国民族医学 | 22篇 |
外科学 | 23775篇 |
综合类 | 30886篇 |
现状与发展 | 32篇 |
一般理论 | 2篇 |
预防医学 | 7686篇 |
眼科学 | 1431篇 |
药学 | 15133篇 |
124篇 | |
中国医学 | 9495篇 |
肿瘤学 | 6165篇 |
出版年
2024年 | 376篇 |
2023年 | 2915篇 |
2022年 | 4096篇 |
2021年 | 7551篇 |
2020年 | 6977篇 |
2019年 | 5503篇 |
2018年 | 5331篇 |
2017年 | 6029篇 |
2016年 | 6807篇 |
2015年 | 6263篇 |
2014年 | 10506篇 |
2013年 | 11751篇 |
2012年 | 9661篇 |
2011年 | 10685篇 |
2010年 | 8654篇 |
2009年 | 8130篇 |
2008年 | 8156篇 |
2007年 | 8309篇 |
2006年 | 7890篇 |
2005年 | 6975篇 |
2004年 | 5741篇 |
2003年 | 5237篇 |
2002年 | 4052篇 |
2001年 | 3622篇 |
2000年 | 3079篇 |
1999年 | 2469篇 |
1998年 | 2266篇 |
1997年 | 2004篇 |
1996年 | 1765篇 |
1995年 | 1495篇 |
1994年 | 1278篇 |
1993年 | 1002篇 |
1992年 | 914篇 |
1991年 | 718篇 |
1990年 | 622篇 |
1989年 | 581篇 |
1988年 | 504篇 |
1987年 | 413篇 |
1986年 | 379篇 |
1985年 | 514篇 |
1984年 | 368篇 |
1983年 | 243篇 |
1982年 | 287篇 |
1981年 | 261篇 |
1980年 | 213篇 |
1979年 | 176篇 |
1978年 | 146篇 |
1977年 | 121篇 |
1976年 | 131篇 |
1975年 | 60篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
81.
82.
肠易激综合征(IBS)是一种常见的功能性疾病,中医病名为"肠郁"。郭朋教授根据IBS生理、病理特点,以疏肝健脾法调和肝脾,辨证施治,取得良好疗效。文章从病因病机、辨证论治及经典案例介绍等几个方面对郭教授治疗IBS经验进行系统阐述,以期为中医药治疗IBS提供理论和方法学参考。 相似文献
83.
84.
85.
Hepatitis E virus (HEV) is the most common cause of acute liver failure (LF) and one of the most common factors causing acute injury in acute-on-chronic LF (ACLF). When HEV-related LF occurs, a series of changes take place in both the intrahepatic environment and extrahepatic microenvironment. The changed types and distribution of immune cells (infiltrating macrophages and increased lymphocytes) in liver tissue, as well the increased proinflammatory cytokines and chemokines in the blood, indicate that the occurrence and progression of HEV-related LF are closely related to immune imbalance. The clinical features and immune reaction in the body during HEV-related acute LF (ALF) and ACLF are complicated. This review highlights recent progress in elucidating the clinical manifestations of HEV-associated ALF and ACLF and discusses the corresponding systemic immune changes and possible regulatory mechanisms. 相似文献
86.
《Annals of hepatology》2019,18(2):397-401
We report the case of a 53-year-old-man who developed human T-cell leukemia virus type-1-associated myelopathy (HAM) after ABO-incompatible liver transplantation for alcoholic liver cirrhosis. The living donor was seropositive for human T-cell leukemia virus type-1 (HTLV-1) and the recipient was seronegative for HTLV-1 before transplantation. After transplantation, the recipient developed steroid-resistant acute cellular rejection, which was successfully treated using anti-thymocyte globulin, and he was eventually discharged. He underwent spinal surgery twice after the transplantation for the treatment of cervical spondylosis that had been present for a period of 9 months before the transplantation. The surgery improved his gait impairment temporarily. However, his gait impairment progressed, and magnetic resonance imaging revealed multiple sites of myelopathy. He was diagnosed with HAM 16 months after the transplantation. Pulse steroid therapy (1000 mg) was administered over a period of 3 days, and his limb paresis improved. Presently, steroid therapy is being continued, with a plan to eventually taper the dose, and he is being carefully followed up at our institution. Our case suggests that liver transplantation involving an HTLV-1-positive living donor carries the risk of virus transmission and short-term development of HAM after transplantation. 相似文献
87.
目的 探究预防性静滴钾离子、镁离子对急性心梗后并发室性心律失常的预防作用。方法 选择2015年1月-2018年1月于西宁市第一人民医院进行治疗的78例急性心肌梗死患者为研究对象,按照随机数字表法将其均分为观察组与对照组,每组各39例患者。对照组患者进行常规急性心梗治疗,观察组患者在对照组基础上加用门冬氨酸钾镁进行治疗,对比两组治疗有效率,对比两组治疗前后血液流变学指标纤维蛋白原(Fib)、凝血酶原时间(PT)、血小板计数(Plt),对比两组治疗期间不良反应发生率及心律失常发生率。结果 治疗后,观察组患者治疗有效率为87.18%,对照组为76.92%,两组对比差异具有统计学意义(P<0.05)。治疗前两组患者Fib、PT以及Plt水平对比差异不具有统计学意义;治疗后,两组患者Plt及Fib水平低于治疗前,PT水平高于治疗前,差异有统计学意义(P<0.05);治疗后观察组患者Plt及Fib水平低于对照组,PT水平高于对照组(P<0.05)。观察组患者不良反应发生率稍高于对照组,但对比差异不具有统计学意义。观察组心律失常发生率为7.69%,对照组为15.38%,两组对比差异具有统计学意义(P<0.05)。结论 预防性静滴钾离子与镁离子能够显著降低急性心梗患者心律失常发生率,同时有利于提高治疗有效率,改善其血流变指标,且安全性较高。 相似文献
88.
PurposeType B aortic dissection is a rare but life-threatening disease. Thoracic endovascular aortic repair (TEVAR) was widely used for Type B aortic dissection patients in the last decade due to the lower mortality and morbidity compared with open chest surgical repair (OCSR). AKI in type B aortic dissection is a well-recognized complication and indicates poor short-term and long-term outcome. The objective of this concise review was to identify the risk factors and the impact of AKI on type B aortic dissection patients.Methods and resultsA literature search was performed using PubMed, Embase, MEDLINE, and Cochrane Library with the search terms ‘type B aortic dissection’ and ‘acute kidney injury’ (AKI), and all English-language literatures published in print or available online from inception through August 2020 were thoroughly reviewed. Studies that reported relative AKI risks and outcomes in type B aortic dissection patient were included. Major mechanisms of AKI in type B aortic dissection included renal hypoperfusion, inflammation response, and the use of contrast medium. Type B aortic dissection patients with AKI significantly had increased hospital stay duration, need of renal replacement therapy, and 30-d and 1-year mortality.ConclusionsAKI in type B aortic dissection is a well-recognized complication and associated with poor short-term and long-term outcome. Early identification of high-risk patients, early diagnosis of AKI, stabilization of the hemodynamic parameters, avoidance of nephrotoxic drugs, and optimization of the use of contrast agents are the major strategies for the reduction of AKI in type B aortic dissection patients. 相似文献
89.
[摘要] 目的 评估直接抗病毒药物(direct antivirus agent, DAA)治疗肝移植术后HCV感染复发的有效性和安全性。方法?回顾性分析首都医科大学附属北京佑安医院2011年2月—2018年12月收治的14例肝移植术后HCV感染复发患者的DAA治疗临床数据,比较患者基线与治疗结束后肝肾功能、血常规、凝血功能、病毒学水平以及无创纤维化评分天冬氨酸转氨酶血小板比率指数(aspartate aminotransferase-platelet ratio index, APRI)的差异。利用电子病历系统和电话随访收集患者治疗期间不良反应发生情况。结果?所有患者均在治疗结束时达到病毒学清除,12周、24周持续病毒学应答率均为100%,DAA治疗后随访17~44个月,期间均未见病毒学复发。与基线水平相比,治疗终点时ALT、AST、TBIL、γ-谷氨酰转移酶以及无创纤维化评分APRI显著下降,WBC、HGB、PLT、CRE、肾小球滤过率和血糖等指标均未见显著变化。DAA治疗期间共3例患者发生不良反应,均为轻度,可自然缓解。结论?肝移植术后HCV感染复发的DAA治疗是安全有效的。 相似文献
90.